Monte Rosa Therapeutics Inc (GLUE)

$GLUE, look for imminent announcement. They just updated their clinical trial for MRT-6160 as completed and increased enrollment to 108 on July 28th. Their Q2 guidance indicated that their partner, Novartis, was looking to advance MRT-6160 in multiple phase 2 studies. The number of autoimmune studies and the size of the patient population for each indication, coupled with the milestone payments that Novartis will pay, could be a significant catalyst since the company is currently trading at a cash value. Hold tight, longs, patience should be rewarded https://clinicaltrials.gov/study/NCT06597799?intr=MRT-6160&rank=1

$GLUE - Monte Rosa Therapeutics Inc. Common Stock - 10Q - Updated Risk Factors GLUE’s 10-Q risk update expands on clinical, regulatory, and financial risks, emphasizing unpredictable economic, trade, and geopolitical shifts—including recent U.S. tariffs and potential retaliations—that could disrupt global markets and development costs. #Biotechnology #GeopoliticalUncertainty #FinancialRisks #RegulatoryRisks #ClinicalRisks 🟢 Added 🟠 Removed https://d-risk.ai/GLUE/10-Q/2025-08-07

$GLUE Monte Rosa Therapeutics Q2 EPS $(0.15) Beats $(0.39) Estimate, Sales $23.19M Beat $10.80M Estimate

$GLUE why so weak?

$GLUE we shall not

$GLUE nice hope we can close above SMA200.

$GLUE MRT‑8102 represents a promising first-in-class therapy targeting NEK7 to modulate the NLRP3 inflammasome. The Phase 1 study is poised to deliver both safety data in healthy volunteers and potentially early efficacy signals in a cardio‑inflammation cohort. We’ll know more by H1 2026—let me know if you’d like updates on milestones or background on NEK7/NLRP3 biology!

$GLUE Monte Rosa (Nasdaq: GLUE) has dosed the first human subjects in their Phase 1 trial of MRT‑8102, a first-in-class molecular glue degrader targeting NEK7, a key protein in the NLRP3 inflammasome implicated in multiple inflammatory diseases

$GLUE Monte Rosa Therapeutics Announces First Subjects Dosed in Phase 1 Study of MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases By Monte Rosa Therapeutics, Inc. | July 21, 2025, 7:00 AM pt$7+

$GLUE highlights to consider: The recent publication in Science magazine as the feature cover article is significant. Not only is this supported by the scientific community (vetting), but it will generate substantial awareness of their AI “Queen” platform, which is groundbreaking in the scientific community for Molecular Glue Degraders (MDG). The company’s AI platform has successfully identified a new pathway to treat undruggable targets, including VAV1. This has been somewhat validated with recent phase 1 results with their MRT-6160 partner drug with Novartis. While all participants were healthy volunteers, the company posted encouraging PD signals hitting various biomarkers correlated to treatment effects with different autoimmune diseases in a previous clinical trial. Utilizing its AI platform, the company has identified close to a hundred drugable targets in huge markets. At a recent major medical conference, the company presented an additional target in the oncology space that showed encouraging promise. The upcoming major catalyst would be the announcement that MRT-6160 is advancing into multiple phase 2b/3 b/trials. The company has stated that they are working with Novartis to expedite this proces. The velocity of share price appreciation would be predicated on the number of indications in the autoimmune space and the guided timing for these trials, in addition the amount of milestone payments trigger. The company’s AI, Queen platform, has essentially discovered the wholly grail for MGD; hence the reason why it was featured on the cover of Science. Since MGD are small molecules which are inexpensive to manufacture and easy to scale, if the company can establish efficacy while maintaining safety in large indications, shareholders should be generously rewarded. Look for other potential partnerships in early stage drugs as another potential catalyst. My research may be biased and is the basis for my investment in the company and I welcome any comments, good luck

$GLUE This might spark things up, or not. https://ir.monterosatx.com/news-releases/news-release-details/monte-rosa-announces-publication-science-key-insights-enable

$GLUE looks good

$GLUE Monte Rosa Therapeutics announces FDA clearance of IND application for MRT-8102 Monte Rosa Therapeutics announced U.S. Food and Drug Administration, FDA, clearance of an Investigational New Drug, IND, application for MRT-8102, a NEK7-directed MGD being developed for the treatment of inflammatory diseases driven by the NLRP3 inflammasome and IL-1beta. The Company plans to initiate a Phase 1 study of MRT-8102 in the coming weeks and anticipates sharing initial results in H1 2026. "The IND clearance of MRT-8102 is another important milestone in our quest to broadly establish MGDs as a modality in immunology and inflammatory indications. MRT-8102, following on the heels of our VAV1-directed MGD MRT-6160, is our second IND specifically for I&I indications, and represents the only clinical-stage MGD that selectively targets NEK7, with potential to address multiple inflammatory diseases, including cardio-immunology, rheumatology, and respiratory indications," said Markus Warmuth, M.D., Chief Executive Officer of Monte Rosa Therapeutics. "We believe MRT-8102 could provide a highly differentiated clinical profile compared to IL-1 antibodies and NLRP3 inhibitors in development based on its potency, selectivity, and long-lasting pharmacodynamics. We look forward to initiating a Phase 1 healthy volunteer study in the coming weeks, with clinical results expected in H1 2026, including data on safety, pharmacokinetics, NEK7 protein degradation, and downstream pharmacodynamic markers."

$GLUE has beaten the last 4 earnings estimates hands down. We should finely see our stock price increase between $6-$6.5 by next earnings.

$GLUE We should start seeing gains in the coming weeks.

$GLUE like dreams can come true five dollars is here again

$GLUE here we go again if any stock needed some Viagra this is certainly one These ups and downs are utterly ridiculous

$GLUE this did better than I thought and a higher volume maybe we will see 5’s again

$GLUE What is going on with this turd?

$GLUE It would not surprise me to hit the 3.40-3.50 floor and then the heavy buying will return. The volume has scaled back and shorting is very heavy.